

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition comprising
a component A comprising one or more ~~compounds that are methyl or methylene donors, which is/are wherein the one or more compounds that are methyl or methylene donors comprise one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine or and serine, or and~~ a physiologically acceptable salt of one of said compounds thereof,
a component B comprising one or more methyl transporters, which is/are ~~wherein the one or more methyl transporters comprise one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, or and 5,10-methenyltetrahydrofolic acid, or a~~ and physiologically acceptable salt of one of said compounds thereof, and
a component C comprising one or more bioflavonoids, which is/are a ~~wherein the one or more bioflavonoids C comprise one or more compounds selected from the group consisting of mono-, di- and triglycoside~~ bioflavonoid ~~bioflavonoids that contain~~ contains an aglycone quercetin.

2. (Cancelled)

3. (Cancelled)

4. (Previously Presented) A composition according to claim 1, wherein component B comprises L-5-methyltetrahydrofolic acid or a physiologically acceptable salt thereof.

5. (Cancelled)

6. (Previously Presented) A composition according to claim 1, wherein component C comprises one or more compounds selected from the group consisting of isoquercetin, quercetin, isoquercitrin, quercimeritrin, spiraeosid, rutin, and hyperin.

7. (Withdrawn) A method of treating or preventing a transmethylation disorder comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

8. (Withdrawn) A method of treating or preventing a cardiovascular disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

9. (Withdrawn) A method of treating or preventing an atherogenic and/or thrombogenic disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

10. (Withdrawn) A method of treating or preventing a disease associated with hyperhomocysteinemia comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

11. (Withdrawn) A method of treating or preventing premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

12. (Cancelled)

13. (Withdrawn) A method of preparing a composition according to claim 1, comprising combining components A, B and C.

14. (Previously Presented) A composition according to claim 1 further comprising one or more nutritional substances, and/or one or more solid, liquid and/or semi liquid excipients or auxiliaries.

15. (Previously Presented) A food or food supplement comprising a component A comprising one or more compounds that are methyl or methylene donors, wherein the one or more compounds that are methyl or methylene donors comprise one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and a physiologically acceptable salt thereof,

a component B comprising one or more methyl transporters, wherein the one or more methyl transporters comprise one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and physiologically acceptable salt thereof, and

a component C comprising one or more bioflavonoids, wherein the one or more bioflavonoids C comprise one or more compounds selected from the group consisting of mono-, di- and triglycoside bioflavonoids that contain an aglycone quercetin.

16. (Previously Presented) A pharmaceutical composition comprising a composition according to claim 1 and one or more pharmaceutically acceptable excipients or auxiliaries.

17. (Previously Presented) A pharmaceutical composition according to claim 16 that is lyophilized.

18. (Previously Presented) A composition according to claim 1, wherein the molar ratio of components A:B:C is 20,000:1:10,000 to 500:1:100.

19. (Previously Presented) A composition according to claim 1, wherein component A comprises one or more compounds selected from the group consisting of betaine, dimethylglycine, sarcosine and serine, and their physiologically acceptable salts, component B comprises one or more compounds selected from the group consisting of dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, and 5,10-methenyltetrahydrofolic acid, and their physiologically acceptable salts, and component C comprises one or more compounds selected from the group consisting of mono-, di- and

triglycoside bioflavonoids that contain an aglycone quercetin.

20. (Cancelled)

21. (Previously Presented) A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of (6S)-tetrahydrofolic acid; 5-methyl-(6S)-tetrahydrofolic acid; 5-formyl-(6S)-tetrahydrofolic acid; 10-formyl-(6R)-tetrahydrofolic acid; 5,10-methylene-(6R)-tetrahydrofolic acid; 5,10-methenyl-(6R)-tetrahydrofolic acid; and their physiologically acceptable salts.

22. (Previously Presented) A composition according to claim 1, wherein component B comprises one or more compounds selected from the group consisting of derivatives of L- and S-glutamic acid.

23. (Previously Presented) A composition according to claim 1, wherein component B comprises 5-methyl-(6S)-tetrahydrofolic acid.

24. (Withdrawn) A method of treating a transmethylation disorder comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

25. (Withdrawn) A method of treating a cardiovascular disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

26. (Withdrawn) A method of treating an atherogenic and/or thrombogenic disease comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

27. (Withdrawn) A method of treating a disease associated with hyperhomocysteinemia comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.

28. (Withdrawn) A method of treating premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1.